<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413608</url>
  </required_header>
  <id_info>
    <org_study_id>P060309</org_study_id>
    <nct_id>NCT00413608</nct_id>
  </id_info>
  <brief_title>Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects</brief_title>
  <official_title>Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test pharmacodynamic response to clopidogrel 150mg once daily during 7 days in healthy
      subjects carriers of a mutated allele (*2) associated with CYP2C19 deficiency and non
      responders to the usual regimen of 75 mg once daily
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty individuals genotyped for specific variants of 2C19 cytochrome and P2Y12 platelet ADP
      receptor will receive during one week a daily dose of 75 mg of clopidogrel. Depending on
      their pharmacodynamic response to this dose of clopidogrel, subjects will be affiliated to
      two groups, &quot;good responders&quot; and &quot;bad responders&quot;. After a wash-out period, &quot;bad responders&quot;
      will receive a double dose of clopidogrel, while the &quot;good responders&quot; will receive 75 mg of
      clopidogrel, associated with a CYP2C19 inhibitor. Such study will allow to evaluate both the
      impact of raising daily dose of clopidogrel in patients with defected variants of 2C19 and
      potential interactions of clopidogrel with other drugs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibition platelet activity index (ADP induced aggregation) measured between</measure>
    <time_frame>during 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clopidogrel and metabolites pharmacokinetics and relation to dynamics</measure>
    <time_frame>during 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers, aged 18 to 35, non smoker, of caucasian origin

          -  Compatible 2C19 and P2Y12 genotypes

          -  Weight 60 kg to 100 kg, and normal BMI

          -  Standard laboratory investigations normal

          -  Negative testing for HIV infection and B and C hepatitis

          -  Basal platelet agregation testing normal

          -  EKG, blood pressure and cardiac frequency in normal range

          -  Ability to understand, follow and sign the protocol

        Exclusion Criteria:

          -  Evolutive medical affection, even treated

          -  Medical history of allergic response to medication or other, peptic ulcer, or known
             hemorrhagic disorder

          -  Laboratory testing out of normal range

          -  Subjects practicing violent sports

          -  Unability to understand or follow the protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Sébastien HULOT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006 Oct 1;108(7):2244-7. Epub 2006 Jun 13.</citation>
    <PMID>16772608</PMID>
  </results_reference>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2006</study_first_submitted>
  <study_first_submitted_qc>December 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2006</study_first_posted>
  <last_update_submitted>May 4, 2011</last_update_submitted>
  <last_update_submitted_qc>May 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Yannick VACHER</name_title>
    <organization>Department Clinical Research of developpement</organization>
  </responsible_party>
  <keyword>Human</keyword>
  <keyword>Adults</keyword>
  <keyword>Male</keyword>
  <keyword>Alleles</keyword>
  <keyword>Genotype</keyword>
  <keyword>Platelet Aggregation/drug effects</keyword>
  <keyword>Platelet Aggregation Inhibitors/*pharmacology</keyword>
  <keyword>Platelet Function Tests</keyword>
  <keyword>Pharmacogenetics</keyword>
  <keyword>*Polymorphism, Genetic</keyword>
  <keyword>Ticlopidine/*analogs &amp; derivatives/pharmacology</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

